8-K: NKGen Biotech Receives Nasdaq Notice Due to Delayed Quarterly Report

NKGen Biotech has received a notification from Nasdaq for failing to file its quarterly report on time, primarily due to a change in accounting firms.

Summary

• NKGen Biotech received a notice from Nasdaq on August 20, 2024, stating they are not compliant with listing rules because they did not file their quarterly report for the period ending June 30, 2024, by the extended deadline of August 19, 2024.
• The delay is partly due to a recent change in the company's independent registered public accounting firm and its valuation firm.
• NKGen has 60 days, until October 21, 2024, to submit a plan to regain compliance.
• Nasdaq may grant an extension of up to 180 days from the original due date, potentially until February 18, 2025, to regain compliance.
• The notice does not immediately affect the trading of NKGen's stock on the Nasdaq Global Market.
• The company is working with its auditors and advisors to file the report as soon as possible to regain compliance within the initial 60-day period.

Sentiment

Score: 4

Explanation: The sentiment is negative due to the non-compliance notice and the risk of delisting, although the company is taking steps to rectify the situation. The change in accounting firms adds uncertainty.

Positives

• The notice from Nasdaq does not immediately affect the listing or trading of the company's stock.
• NKGen is actively working with auditors and advisors to file the report promptly.
• The company intends to regain compliance within the initial 60-day period, avoiding the need for a formal plan.

Negatives

• NKGen Biotech failed to file its quarterly report by the extended deadline, resulting in a non-compliance notice from Nasdaq.
• The delay is partly due to a change in the company's accounting and valuation firms, which suggests potential internal issues.
• There is a risk of delisting if the company does not regain compliance within the allotted time.

Risks

• There is a risk that NKGen may not regain compliance with Nasdaq listing rules within the given timeframes.
• The company may face delisting if it fails to submit a plan or regain compliance within the extended period.
• The change in accounting and valuation firms could indicate underlying financial or operational challenges.
• The company's ability to raise additional funding to complete the development of its product candidates is a risk.

Future Outlook

The company intends to file the Form 10-Q as promptly as possible to regain compliance with Nasdaq listing rules. There are forward-looking statements regarding the development of SNK01 and other product candidates, but these are subject to risks and uncertainties.

Management Comments

• The Company is actively working with its auditors and advisors and intends to file the Form 10-Q as promptly as possible in order to regain compliance with the Rule within the 60-day period described above.

Industry Context

This announcement highlights the importance of timely financial reporting for publicly listed companies. Delays in filing can lead to compliance issues and potential delisting, which can negatively impact investor confidence. This is a common issue for companies undergoing changes in their accounting or valuation firms.

Comparison to Industry Standards

• Many biotech companies face challenges in meeting reporting deadlines, especially during periods of change or rapid growth.
• Companies like Cassava Sciences (SAVA) and Ocugen (OCGN) have also faced scrutiny and delays in reporting, highlighting the industry-wide challenges in maintaining compliance.
• The 60-day period to submit a plan is standard for Nasdaq, and the potential 180-day extension is also a common practice to allow companies to rectify issues.
• Compared to other companies, NKGen's situation is not unique, but the change in accounting firms adds a layer of complexity that needs to be addressed promptly.

Stakeholder Impact

• Shareholders may experience uncertainty due to the non-compliance notice and potential delisting.
• Employees may be affected by the company's financial and operational challenges.
• Creditors and suppliers may be concerned about the company's ability to meet its obligations.

Next Steps

• NKGen Biotech needs to file its Form 10-Q as soon as possible.
• The company must submit a plan to regain compliance to Nasdaq by October 21, 2024, if the report is not filed by then.
• The company will continue to work with its auditors and advisors to resolve the issue.

Key Dates

Keywords

Nasdaq, compliance, quarterly report, Form 10-Q, delayed filing, accounting firm, valuation firm, delisting, NKGen Biotech, NKGN